| Bioactivity | JNJ-26076713 is a potent and orally active alpha V integrin antagonist with IC50 values of 2.3 nM and 6.3 nM for alpha(V)beta(3) and alpha(V)beta(5), respectively. JNJ-26076713 inhibits retinal neovascularization[1]. |
| Invitro | JNJ-26076713 (5-5000 nM) 以剂量依赖的方式抑制 FGF2 诱导的 HUVEC 迁移[1]。JNJ-26076713 (0.1, 1, 和 10 μg) 以剂量依赖的方式抑制鸡胚绒毛尿囊膜 (CAM) 模型的血管生成[1]. |
| In Vivo | JNJ-26076713 (30-120 mg/kg; i.g.; 每天两次, 连续5天; 氧诱导视网膜病变 (OIR) 模型C57BL/6J 小鼠) 以剂量依赖的方式抑制视网膜新生血管[1]。JNJ-26076713 (60 mg/kg; i.g.; 每天两次, 连续5天; 糖尿病 Long-Evans 大鼠) 抑制与糖尿病相关的视网膜血管通透性和白细胞瘀血的增加[1]。 Animal Model: |
| Name | JNJ-26076713 |
| CAS | 669076-03-3 |
| Formula | C29H38N4O3 |
| Molar Mass | 490.64 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Santulli RJ, et, al. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. J Pharmacol Exp Ther. 2008 Mar;324(3):894-901. |
JNJ-26076713
CAS: 669076-03-3 F: C29H38N4O3 W: 490.64
JNJ-26076713 is a potent and orally active alpha V integrin antagonist with IC50 values of 2.3 nM and 6.3 nM for alpha(V
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.